Phenex AG pursues drug discovery projects on nuclear receptors with the aim to develop novel drug candidates for the treatment of metabolic disorders and other severe diseases with a high unmet medical need. To reach this goal, Phenex has developed an in house Screening Platform with a wide array of relevant assays and compound libraries.
Using this platform, Phenex has identified a novel proprietary FXR Agonist that is now developed clinically for Type 2 Diabetes and Metabolic Syndrome. The company has secured appropriate funds to enable R&D activities for multiple years.
Currently there are no open positions available.